Key facts
| Price (PPV) | 108.70 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | irbésartan |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09CA04 |
| Manufacturer | SOTHEMA |
| Presentation | Boite de 28 |
| Nature | Médicament |
| Hospital price | 67.90 MAD |
| Data collected on | 9/8/2026 |
Indications
L’irbersartan est indiqué chez l’adulte dans le traitement de l’ hypertension artérielle essentielle. Il est également indiqué dans le traitement de l’atteinte rénale chez les patients adultes hypertendus diabétiques de type 2, dans le cadre de la prise en charge par un médicament antihypertenseur.
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Irbesar Sun 150 mg (SUN PHARMACEUTICALS NORTH AFRICA S.A) contains the same active substance as Vepran 150 mg (Irbésartan) at the same strength, but in a different pack: Boite de 14 at 60.90 MAD, i.e. 4.35 MAD per unit against 3.88 MAD for Vepran 150 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
Same pack size
| Product | Manufacturer | Pack | PPV | Unit price | Difference |
|---|---|---|---|---|---|
| Aprovel 150 mg | SANOFI AVENTIS MAROC | Boîte de 28 | 108.70 MAD | 3.88 / unit | — |
| Irbesar Sun 150 mg | SUN PHARMACEUTICALS NORTH AFRICA S.A | Boite de 28 | 108.70 MAD | 3.88 / unit | — |
| Avepro 150 mg | SOTHEMA | Boite de 28 | 120 MAD | 4.29 / unit | — |
Other pack sizes
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Irbesar Sun 150 mg | SUN PHARMACEUTICALS NORTH AFRICA S.A | Boite de 14 | 60.90 MAD | 4.35 / unit |
| Avepro 150 mg | SOTHEMA | Boite de 14 | 64 MAD | 4.57 / unit |
| Vezar 150 mg | SYNTHEMEDIC | Boite de 30 | 88.50 MAD | 2.95 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Vepran 150 mg
Vepran 150 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by SOTHEMA and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Vepran 150 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Vepran 150 mg
Answers to common questions from Moroccan patients about this drug.